Tag: Multiple Sclerosis
Menopause Not Tied to Worsening Multiple Sclerosis Disability
Authors say increases in disability seen around age 50 years are likely due to other aging processes
Consistent Link Seen Between Prodromal Symptoms, MS Risk
MS cases more likely to have coded autonomic, cognitive, neurological, pain, psychiatric symptoms in the five years preceding diagnosis
Postmenopausal Women With MS Have More Comorbidities
Higher prevalence of cardiovascular disease, endocrine/metabolic disorders seen in postmenopausal than premenopausal women
Higher Ultraprocessed Food Intake Tied to Increased Multiple Sclerosis Disease Activity
Findings seen for relapses and active new lesions at two to five years
Ocrelizumab Provides Superior Relapse Control in Multiple Sclerosis
Control of relapses improved compared with fingolimod, natalizumab, and alemtuzumab
Industry Payments Common Among Neurologists Prescribing MS Drugs
Nearly 80 percent of neurologists received payments; higher prescription volumes linked to higher receipt of payments
Broader Formulary Coverage Linked to Lower Odds of MS Relapse
Lower odds of relapse seen among Medicare beneficiaries in prescription drug plans, Medicare Advantage Prescription Drug plans
Increase Seen in Physician Visits ~15 Years Before MS Onset
All-cause physician visit rate ratios consistently elevated from 14 years before onset, peaking in the year before MS onset
Women With MS Less Likely Than Men to Receive Disease-Modifying Therapies
Proportion of treated women began to decline 18 months before childbirth, reaching 27.9 percent at the estimated time of conception
Greater Epigenetic Age Seen in Patients With Pediatric-Onset MS
For two of the four epigenetic clocks used, the difference in epigenetic age was significant












